Clinical challenges in Advanced Melanoma: Immunotherapy or BRAF-Targeted Therapy
Originally presented at HOPA's 14th Annual Conference, March 2018.
The treatment of unresectable and metastatic melanoma has been constantly evolving over the last several years, largely because of the clinical benefit and success of immune checkpoint inhibitors and targeted therapies for BRAF-mutant melanoma. More recently, this evolution has also moved into the adjuvant setting for those with resected malignant melanoma. In this session we will navigate through recent clinical trial data and discuss how to apply this information, given the heterogeneity of the melanoma patient population. As a way to guide optimal treatment decisions, we will also address the ongoing controversy about when to initiate therapy with immune checkpoint inhibitors versus oral combination targeted therapy. Finally, we will identify key clinical trials currently being conducted to help resolve clinical challenges in treating malignant melanoma.
Jaime Anderson, PharmD BCOP
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.
This activity has been approved for .1 CEU
This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.
Release Date: September 26, 2018
Expiration Date: March 22, 2021